Introduction to Therapies Used to Treat SMA

EP: 1.Describing SMA Progression Over Time

EP: 2.Unmet Needs of Older Patients Living With SMA

EP: 3.Examining the Importance of Early Treatment for SMA

EP: 4.Key Functional Milestones Affected by Disease Progression

EP: 5.The Importance of Supportive Care for Patients Living With SMA

Now Viewing

EP: 6.Introduction to Therapies Used to Treat SMA

EP: 7.Splicing Modifiers and Gene Therapy for SMA

EP: 8.Key Clinical Considerations for the Management of SMA

EP: 9.Assessing Different Factors When Selecting a Treatment

EP: 10.Evaluating the Potential of Intrathecal Gene Therapy

EP: 11.Other Investigational Treatment Options for SMA

EP: 12.Insurance Considerations for SMA Therapies

EP: 13.Optimizing Multidisciplinary Care Approaches for the Future of SMA Management

EP: 14.Final Panel Thoughts on the Management of SMA

Clinical Brief: Historical and Current Treatment Paradigms for SMA

Main Discussion Topics

• Evolution of SMA care from supportive/palliative to disease-modifying approaches
• Description of current FDA-approved disease-modifying therapies
• Mechanisms of action for available SMA treatments
• Challenges in accurately measuring treatment response

Key Points for Physicians

• Before disease-modifying therapies, SMA care focused on respiratory support, nutrition, orthopedic management, and pain control.
• Current treatment options include nusinersen (intrathecal antisense oligonucleotide), risdiplam (oral splicing modifier), and onasemnogene abeparvovec (gene therapy, limited to children younger than 2 years).
• Nusinersen and risdiplam enhance SMN protein production from the SMN2 gene.
• Standardized assessment tools have limitations at both ends of the functional spectrum.

Notable Insights

Implementation of consensus care guidelines and multidisciplinary care improved survival outcomes even before disease-modifying therapies were available, highlighting the importance of comprehensive care approaches.

Clinical Significance

The treatment paradigm for SMA has evolved from palliative care to a multifaceted approach combining disease-modifying therapies with supportive care, requiring ongoing adaptation of assessment methods to capture meaningful clinical outcomes.